US011058647B1

(12) **United States Patent**
Goren et al.

(10) **Patent No.: US 11,058,647 B1**
(45) **Date of Patent: Jul. 13, 2021**

(54) **SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION**

(71) Applicant: **Applied Biology, Inc.**, Irvine, CA (US)

(72) Inventors: **Ofer A. Goren**, Irvine, CA (US); **John McCoy**, Irvine, CA (US)

(73) Assignee: **Applied Biology, Inc.**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/946,875**

(22) Filed: **Jul. 9, 2020**

Related U.S. Application Data

(63) Continuation-in-part of application No. 15/929,788, filed on May 21, 2020.

(60) Provisional application No. 63/041,426, filed on Jun. 19, 2020, provisional application No. 62/704,531, filed on May 14, 2020, provisional application No. 62/704,416, filed on May 8, 2020, provisional application No. 62/704,126, filed on Apr. 22, 2020, provisional application No. 63/004,398, filed on Apr. 2, 2020, provisional application No. 63/004,171, filed on Apr. 2, 2020, provisional application No. 63/001,629, filed on Mar. 30, 2020.

(51) **Int. Cl.**

A61K 31/445	(2006.01)
A61K 31/335	(2006.01)
A61K 31/201	(2006.01)
A61K 31/192	(2006.01)
A61K 31/12	(2006.01)
A61K 31/4427	(2006.01)
A61K 31/4164	(2006.01)
A61K 31/4152	(2006.01)
A61K 31/16	(2006.01)
A61K 38/03	(2006.01)
A61P 11/00	(2006.01)
A61P 31/14	(2006.01)
A61K 31/05	(2006.01)
A61K 31/4166	(2006.01)
A61K 31/473	(2006.01)
A61K 31/4439	(2006.01)
A61K 31/57	(2006.01)
C07K 16/28	(2006.01)
A61K 31/4709	(2006.01)
A61K 31/277	(2006.01)
A61K 31/437	(2006.01)
A61K 38/09	(2006.01)
C12N 15/113	(2010.01)
A61K 33/18	(2006.01)
A61K 31/4155	(2006.01)
A61K 31/58	(2006.01)
A61K 31/337	(2006.01)
C07K 14/71	(2006.01)
A61K 31/167	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/05*** (2013.01); ***A61K 31/167*** (2013.01); ***A61K 31/277*** (2013.01); ***A61K 31/337*** (2013.01); ***A61K 31/4155*** (2013.01); ***A61K 31/4164*** (2013.01); ***A61K 31/4166*** (2013.01); ***A61K 31/437*** (2013.01); ***A61K 31/4439*** (2013.01); ***A61K 31/473*** (2013.01); ***A61K 31/4709*** (2013.01); ***A61K 31/57*** (2013.01); ***A61K 31/58*** (2013.01); ***A61K 33/18*** (2013.01); ***A61K 38/09*** (2013.01); ***A61P 31/14*** (2018.01); ***C07K 14/71*** (2013.01); ***C07K 16/2827*** (2013.01); ***C12N 15/1136*** (2013.01); *C12N 2310/11* (2013.01)

(58) **Field of Classification Search**
CPC .. A61K 31/445; A61K 31/335; A61K 31/201; A61K 31/192; A61K 31/12; A61K 31/4427; A61K 31/4164; A61K 31/4152; A61K 31/16; A61K 38/03; A61P 11/00; A61P 31/14
USPC 514/3.7, 327, 341, 391, 404, 453, 560, 514/569, 618, 628, 629, 680
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2019/0209469 A1 7/2019 Patel et al.

OTHER PUBLICATIONS

Office Action cited in U.S. Appl. No. 15/929,788 dated Mar. 9, 2021.

Primary Examiner — Raymond J Henley, III
(74) *Attorney, Agent, or Firm* — Buchanan Ingersoll & Rooney PC

(57) **ABSTRACT**

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

7 Claims, No Drawings